Adherence positive (≥ 70% participation in the intervention sessions) | Adherence negative (< 70% participation in the intervention sessions) | P-value | |
---|---|---|---|
Nutrition courses | 21/26 (81%) | 5/26 (19%) | |
Cancer, n | 16 | 2 | 0.610 |
Age*, years | 43 (29–72) | 41 (28–49) | 0.686 |
BMI*, kg/m2 | 23 (18–45) | 24 (20–37) | 0.610 |
VO2peak*, ml/kg/min | 24 (12–42) | 23 (16–41) | 0.952 |
O2 at VT1*, ml/kg/min | 14 (8–28) | 14 (10–21) | 0.343 |
IPAQ, MET*min/wk | 5130 (347–14,166) | 6167 (4583–7812) | 0.629 |
Training courses | 21/26 (81%) | 5/26 (19%) | |
Cancer, n | 14 | 4 | 0.114 |
Age*, years | 42 (28–72) | 41 (36–51) | 0.286 |
BMI*, kg/m2 | 23 (18–45) | 24 (20–37) | 0.857 |
VO2peak*, ml/kg/min | 24 (12–42) | 22 (16–37) | 0.467 |
O2 at VT1*, ml/kg/min | 14 (8–28) | 15 (10–21) | 1.000 |
IPAQ, MET*min/wk | 5376 (347–14,166) | 5375 (2826–7812) | 0.970 |
Nutrition and training | 19/26 (73%) | 7/26 (27%) | |
Cancer, n | 14 | 4 | 0.534 |
Age*, years | 43 (29–27) | 41 (28–51) | 0.821 |
BMI*, kg/m2 | 23 (18–45) | 24 (20–37) | 0.778 |
VO2peak*, ml/kg/min | 24 (12–42) | 23 (16–41) | 0.955 |
O2 at VT1*, ml/kg/min | 14 (8–28) | 15 (10–21) | 0.642 |
IPAQ, MET*min/wk | 5376 (347–14,166) | 5576 (2826–7812) | 0.974 |